[{"address1": "120 Presidential Way", "address2": "Suite 330", "city": "Woburn", "state": "MA", "zip": "01801", "country": "United States", "phone": "781 245 1325", "website": "https://www.biofrontera-us.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Dr. Hermann  Luebbert Ph.D.", "age": 68, "title": "CEO, President & Chairman", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 784789, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eugene Frederick Leffler III", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1985, "fiscalYear": 2024, "totalPay": 502908, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erica F. Gates CPA, M.B.A.", "title": "Senior Director of Finance & Principal Accounting Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jon  Lyons M.B.A., Ph.D.", "title": "Vice President of Scientific & Medical Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Hakansson J.D.", "title": "General Counsel & Head of Compliance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Baldyga", "title": "Vice President of Sales & Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 1.17, "open": 1.19, "dayLow": 1.11, "dayHigh": 1.19, "regularMarketPreviousClose": 1.17, "regularMarketOpen": 1.19, "regularMarketDayLow": 1.11, "regularMarketDayHigh": 1.19, "beta": 0.298, "trailingPE": 1.0172414, "forwardPE": -1.0260869, "volume": 217379, "regularMarketVolume": 217379, "averageVolume": 876554, "averageVolume10days": 218950, "averageDailyVolume10Day": 218950, "bid": 1.13, "ask": 1.19, "bidSize": 200, "askSize": 200, "marketCap": 10471237, "fiftyTwoWeekLow": 0.651, "fiftyTwoWeekHigh": 2.43, "priceToSalesTrailing12Months": 0.29614902, "fiftyDayAverage": 1.07682, "twoHundredDayAverage": 1.082155, "currency": "USD", "enterpriseValue": 7257069, "profitMargins": -0.36306, "floatShares": 5099136, "sharesOutstanding": 8873930, "sharesShort": 220614, "sharesShortPriorMonth": 292393, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0249, "heldPercentInsiders": 0.20712, "heldPercentInstitutions": 0.36470002, "shortRatio": 0.25, "shortPercentOfFloat": 0.0249, "impliedSharesOutstanding": 8873930, "bookValue": 0.847, "priceToBook": 1.3931522, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -12837000, "trailingEps": 1.16, "forwardEps": -0.86, "lastSplitFactor": "1:20", "lastSplitDate": 1688515200, "enterpriseToRevenue": 0.205, "enterpriseToEbitda": -0.385, "52WeekChange": 0.017391324, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BFRI", "underlyingSymbol": "BFRI", "shortName": "Biofrontera Inc.", "longName": "Biofrontera Inc.", "firstTradeDateEpochUtc": 1635514200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f81dad8d-7768-38b3-a53c-f0f095b62379", "messageBoardId": "finmb_531568773", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.18, "targetHighPrice": 16.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 2881000, "totalCashPerShare": 0.372, "ebitda": -18851000, "totalDebt": 994000, "quickRatio": 0.703, "currentRatio": 1.535, "totalRevenue": 35358000, "debtToEquity": 17.975, "revenuePerShare": 8.497, "returnOnAssets": -0.45997003, "returnOnEquity": -3.9089499, "grossProfits": 16655000, "freeCashflow": -19120376, "operatingCashflow": -18119000, "revenueGrowth": 0.013, "grossMargins": 0.47104, "ebitdaMargins": -0.53314996, "operatingMargins": -0.55038, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]